Sanofi's experimental eczema treatment amlitelimab achieved its primary endpoints across three late-stage clinical trials, but the results have raised concerns about the drug's safety profile and overall efficacy. The treatment targets the OX40 ligand, a protein involved in immune system regulation that plays a role in inflammatory skin conditions.
The Phase 3 trials evaluated amlitelimab in patients with moderate-to-severe atopic dermatitis, though specific efficacy rates and patient population details were not disclosed in the initial results. While the drug technically met its primary goals, the mixed nature of the data has prompted questions about its clinical meaningfulness compared to existing eczema treatments.